4-[5,7,11-trihydroxy-2-(hydroxymethyl)-15-methyltetracyclo[8.7.0.02,7.011,15]heptadecan-14-yl]-2,5-dihydrofuran-2-one

• ChemBase ID: 134363
• Molecular Formular: C23H34O6
• Molecular Mass: 406.51246
• Monoisotopic Mass: 406.23553881
• SMILES: CC12CCC3C(C1(CCC2C1=CC(=O)OC1)O)CCC1(C3(CCC(C1)O)CO)O
• Canonical SMILES: OCC12CCC(CC2(O)CCC2C1CCC1(C2(O)CCC1C1=CC(=O)OC1)C)O
• InChI: InChI=1S/C23H34O6/c1-20-6-3-17-18(4-8-22(27)11-15(25)2-7-21(17,22)13-24)23(20,28)9-5-16(20)14-10-19(26)29-12-14/h10,15-18,24-25,27-28H,2-9,11-13H2,1H3
• InChIKey: ZNDMLUUNNNHNKC-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 4-[5,7,11-trihydroxy-2-(hydroxymethyl)-15-methyltetracyclo[8.7.0.0^2,^7.0^1^1,^1^5]heptadecan-14-yl]-2,5-dihydrofuran-2-one
• IUPAC Traditional name: 4-[5,7,11-trihydroxy-2-(hydroxymethyl)-15-methyltetracyclo[8.7.0.0^2,^7.0^1^1,^1^5]heptadecan-14-yl]-5H-furan-2-one
• Synonyms: 3β,5,14,19-Tetrahydroxy-5β,20(22)-cardenolide; 5β,20(22)-Cardenolide-3β,5,14,19-tetrol; K-Strophanthidol; Strophanthidol

Database IDs

• CAS Number: 560-54-3
• EC Number: 209-211-4
• MDL Number: MFCD00056528
• PubChem SID: 24899677; 162228639
• PubChem CID: 544146

CALCULATED PROPERTIES

• Acid pKa: 7.1826363
• H Acceptors: 5
• H Donor: 4
• LogD (pH = 5.5): 0.54557186
• LogD (pH = 7.4): 0.13214006
• Log P: 0.5544897
• Molar Refractivity: 106.8998 cm^3
• Polarizability: 42.497013 Å^3
• Polar Surface Area: 107.22 Å^2
• Rotatable Bonds: 2
• Lipinski's Rule of Five: true

PROPERTIES

Safety Information

• RTECS: FH5325000
• European Hazard Symbols: Toxic (T)
• UN Number: 2811
• German water hazard class: 3
• Hazard Class: 6.1
• Packing Group: 3
• Risk Statements: 23/24/25
• Safety Statements: 45
• GHS Pictograms: GHS06
• GHS Signal Word: Danger
• GHS Hazard statements: H301-H311-H331
• GHS Precautionary statements: P261-P280-P301 + P310-P311
• Personal Protective Equipment: Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
• RID/ADR: UN 2811 6.1/PG 3

DETAILS

Sigma Aldrich - S5883

General description
Reduced aglycone of K-strophanthin and cymarin, one of the primary excretion products after use of the glycosides in treatment of congestive heart failure.1